Direct attack on RAS: Intramolecular communication and mutation-specific effects

Clinical Cancer Research

Volumn 21, Issue 8, 2015, Pages 1810-1818

  Marcus, Kendra ^a   Mattos, Carla ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANOSINE TRIPHOSPHATE; RAS PROTEIN; ANTINEOPLASTIC AGENT; ISOPROTEIN; PROTEIN BINDING; PROTEIN P21;

ALLOSTERISM; BINDING AFFINITY; BINDING SITE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME STRUCTURE; GENE MUTATION; HIGH THROUGHPUT SCREENING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; NEOPLASMS;

ALLOSTERIC REGULATION; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CATALYTIC DOMAIN; GUANOSINE TRIPHOSPHATE; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; ONCOGENE PROTEIN P21(RAS); PROTEIN BINDING; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION;

EID: 84927641895     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2148     Document Type: Review

References (86)

1. Cox AD, Der CJ. Ras history: the saga continues. Small GTPases 2010;1:2-27.
2. McCormick F. KRAS as a therapeutic target. Clin Cancer Res 2015;21:1797-801.
3. Cox AD, Der CJ, Philips MR. Targeting RAS membrane association: back to the future for anti-RAS drug discovery? Clin Cancer Res 2015;21:1819-27.
4. Kimmelman AC. Metabolic dependencies in RAS-driven cancers. Clin Cancer Res 2015;21:1828-34.
5. Downward J. RAS synthetic lethal screens revisited: still seeking the elusive prize? Clin Cancer Res 2015;21:1802-9.
6. Bos JL, Rehmann H, Wittinghofer A. GEFs and GAPs: critical elements in the control of small G proteins. Cell 2007;129:865-77.
7. Henis YI, Hancock JF, Prior IA. Ras acylation, compartmentalization, and signaling nanoclusters. Mol Membr Biol 2009;26:80-92.
8. Milburn MV, Tong L, deVos AM, Brunger A, Yamaizumi Z, Nishimura S, et al. Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins. Science 1990;247:939-45.
9. Geyer M, Schweins T,Herrmann C, Prisner T, Wittinghofer A, Kalbitzer HR. Conformational transitions in p21ras and in its complexes with the effector protein Raf-RBD and the GTPase activating protein GAP. Biochemistry 1996;35:10308-20.
10. Spoerner M, Hozsa C, Poetzl JA, Reiss K, Ganser P, Geyer M, et al. Conformational states of human rat sarcoma (Ras) protein complexed with its natural ligand GTP and their role for effector interaction and GTP hydrolysis. J Biol Chem 2010;285:39768-78.
11. Ito Y, Yamasaki K, Iwahara J, Terada T, Kamiya A, Shirouzu M, et al. Regional polysterism in the GTP-bound form of the human c-Ha-Ras protein. Biochemistry 1997;36:9109-19.
12. John J, Frech M, Wittinghofer A. Biochemical properties of Ha-ras encoded p21 mutants and mechanism of the autophosphorylation reaction. J Biol Chem 1988;263:11792-9.
13. Buhrman G, Holzapfel G, Fetics S, Mattos C. Allosteric modulation of Ras positions Q61 for a direct role in catalysis. Proc Natl Acad Sci U S A 2010;107:4931-6.
14. Buhrman G, Kumar VS, Cirit M, Haugh JM, Mattos C. Allosteric modulation of Ras-GTP is linked to signal transduction through RAF kinase. J Biol Chem 2011;286:3323-31.
15. Fetics S, Guterres H, Kearney BM, Buhrman G, Ma B, Nussinov R, et al. Allosteric effects of the oncogenic RasQ61L mutant on Raf-RBD. Structure 2015;23:1-12.
16. Johnson CW, Mattos C. The allosteric switch and conformational states in Ras GTPase affected by small molecules. Enzymes 2013;33:41-67.
17. Stephen AG, Esposito D, Bagni RK, McCormick F. Dragging ras back in the ring. Cancer Cell 2014;25:272-81.
18. Thompson H. US National Cancer Institute's new Ras project targets an old foe. Nat Med 2013;19:949-50.
19. Chandrashekar R, Adams PD. Prospective development of small molecule targets to oncogenic Ras proteins. Open J Biophys 2013;3:207-11.
20. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov 2014;13:828-51.
21. Ebi H, Faber AC, Engelman JA, Yano S. Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers. Cancer Sci 2014;105:499-505.
22. Mattingly RR. Activated ras as a therapeutic target: constraints on directly targeting ras isoforms and wild-type versus mutated proteins. ISRN Oncol 2013;2013:536529.
23. Spiegel J, Cromm PM, Zimmermann G, Grossmann TN, Waldmann H. Small-molecule modulation of Ras signaling. Nat Chem Biol 2014;10:613-22.
24. Vivanco I. Targeting molecular addictions in cancer. Br J Cancer 2014;111:2033-8.
25. Wang W, Fang G, Rudolph J. Ras inhibition via direct Ras binding - is there a path forward? Bioorg Med Chem Lett 2012;22:5766-76.
26. Wang Y, Kaiser CE, Frett B, Li HY. Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators. J Med Chem 2013;56:5219-30.
27. Downward J. RAS's cloak of invincibility slips at last? Cancer Cell 2014;25:5-6.
28. Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res 2012;72:2457-67.
29. Ahmadian MR, Stege P, Scheffzek K, Wittinghofer A. Confirmation of the arginine-finger hypothesis for the GAP-stimulated GTP-hydrolysis reaction of Ras. Nat Struct Biol 1997;4:686-9.
30. Scheffzek K, Ahmadian MR, Kabsch W, Wiesmuller L, Lautwein A, Schmitz F, et al. The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 1997;277:333-8.
31. Colombo S, Peri F, Tisi R, Nicotra F, Martegani E. Design and characterization of a new class of inhibitors of ras activation. Ann N Y Acad Sci 2004;1030:52-61.
32. Hocker HJ, Cho KJ, Chen CY, Rambahal N, Sagineedu SR, Shaari K, et al. Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function. Proc Natl Acad Sci U S A 2013;110:10201-6.
33. Lim SM, Westover KD, Ficarro SB, Harrison RA, Choi HG, Pacold ME, et al. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. Angew Chem Int Ed Engl 2014;53:199-204.
34. Maurer T, Garrenton LS, Oh A, Pitts K, Anderson DJ, Skelton NJ, et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci USA 2012;109:5299-304.
35. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013;503:548-51.
36. Patgiri A, Yadav KK, Arora PS, Bar-Sagi D. An orthosteric inhibitor of the Ras-Sos interaction. Nat Chem Biol 2011;7:585-7.
37. Sacco E, Abraham SJ, Palmioli A, Damore G, Bargna A, Mazzoleni E, et al. Binding properties and biological characterization of new sugar-derived Ras ligands. Med Chem Commun 2011;2:396-401.
38. Schopel M, Jockers KF, Duppe PM, Autzen J, Potheraveedu VN, Ince S, et al. Bisphenol A binds to Ras proteins and competes with guanine nucleotide exchange: implications for GTPase-selective antagonists. J Med Chem 2013;56:9664-72.
39. Sun Q, Burke JP, Phan J, Burns MC, Olejniczak ET, Waterson AG, et al. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew Chem Int Ed Engl 2012;51:6140-3.
40. Barnard D, Sun H, Baker L, Marshall MS. In vitro inhibition of Ras-Raf association by short peptides. Biochem Biophys Res Commun 1998;247:176-80.
41. Clark GJ, Drugan JK, Terrell RS, Bradham C, Der CJ, Bell RM, et al. Peptides containing a consensus Ras binding sequence from Raf-1 and theGTPase activating protein NF1 inhibit Ras function. Proc Natl Acad Sci U S A 1996;93:1577-81.
42. Karaguni IM, Glusenkamp KH, Langerak A, Geisen C, Ullrich V, Winde G, et al. New indene-derivatives with anti-proliferative properties. Bioorg Med Chem Lett 2002;12:709-13.
43. Kato-Stankiewicz J, Hakimi I, Zhi G, Zhang J, Serebriiskii I, Guo L, et al. Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proc Natl Acad Sci U S A 2002;99:14398-403.
44. Rosnizeck IC, Graf T, Spoerner M, Trankle J, Filchtinski D, Herrmann C, et al. Stabilizing a weak binding state for effectors in the human ras protein by cyclen complexes. Angew Chem Int Ed Engl 2010;49:3830-3.
45. Shima F, Yoshikawa Y, Matsumoto S, Kataoka T. Discovery of small-molecule Ras inhibitors that display antitumor activity by interfering with Ras. GTP-effector interaction. Enzymes 2013;34:1-23.
46. Shima F, Yoshikawa Y, Ye M, Araki M, Matsumoto S, Liao J, et al. In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction. Proc Natl Acad Sci U S A 2013;110:8182-7.
47. Upadhyaya P, Qian Z, Habir NA, Pei D. Direct ras inhibitors identified from a structurally rigidified bicyclic peptide library. Tetrahedron 2014;70:7714-20.
48. Waldmann H, Karaguni IM, Carpintero M, Gourzoulidou E, Herrmann C, Brockmann C, et al. Sulindac-derived Ras pathway inhibitors target the Ras-Raf interaction and downstream effectors in the Ras pathway. Angew Chem Int Ed Engl 2004;43:454-8.
49. Wu X, Upadhyaya P, Villalona-Calero MA, Briesewitz R, Pei D. Inhibition of Ras-effector interaction by cyclic peptides. Med Chem Commun 2013;4:378-82.
50. Smith MJ, Neel BG, Ikura M. NMR-based functional profiling of RASopathies and oncogenic RAS mutations. Proc Natl Acad Sci U S A 2013;110:4574-9.
51. Hayes TK, Der CJ. Mutant and wild-type Ras: co-conspirators in cancer. Cancer Discov 2013;3:24-6.
52. Young A, Lou D, McCormick F. Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov 2013;3:112-23.
53. Muraoka S, Shima F, Araki M, Inoue T, Yoshimoto A, Ijiri Y, et al. Crystal structures of the state 1 conformations of the GTP-bound H-Ras protein and its oncogenic G12V and Q61L mutants. FEBS Lett 2012;586:1715-8.
54. Abankwa D, Gorfe AA, Inder K, Hancock JF. Ras membrane orientation and nanodomain localization generate isoform diversity. Proc Natl Acad Sci U S A 2010;107:1130-5.
55. Abankwa D, Hanzal-Bayer M, Ariotti N, Plowman SJ, Gorfe AA, Parton RG, et al. A novel switch region regulates H-ras membrane orientation and signal output. EMBO J 2008;27:727-35.
56. Kearney BM, Johnson CW, Roberts DM, Swartz P, Mattos C. DRoP: a water analysis program identifies Ras-GTP-specific pathway of communication between membrane-interacting regions and the active site. J Mol Biol 2014;426:611-29.
57. Gorfe AA, Grant BJ, McCammon JA. Mapping the nucleotide and isoform-dependent structural and dynamical features of Ras proteins. Structure 2008;16:885-96.
58. Buhrman G, O'Connor C, Zerbe B, Kearney BM, Napoleon R, Kovrigina EA, et al. Analysis of binding site hot spots on the surface of Ras GTPase. J Mol Biol 2011;413:773-89.
59. Gorfe AA, Hanzal-Bayer M, Abankwa D, Hancock JF, McCammon JA. Structure and dynamics of the full-length lipid-modified H-Ras protein in a 1,2-dimyristoylglycero-3-phosphocholine bilayer. J Med Chem 2007;50:674-84.
60. Parker JA, Mattos C. The Ras-membrane interface: isoform-specific differences in the catalytic domain. Mol Cancer Res 2015 Jan 7. [Epub ahead of print].
61. O'Connor C, Kovrigin EL. Global conformational dynamics in ras. Biochemistry 2008;47:10244-6.
62. Kraulis PJ, Domaille PJ, Campbell-Burk SL, Van Aken T, Laue ED. Solution structure and dynamics of ras p21.GDP determined by heteronuclear three- and four-dimensional NMR spectroscopy. Biochemistry 1994;33:3515-31.
63. Grant BJ, Lukman S, Hocker HJ, Sayyah J, Brown JH, McCammon JA, et al. Novel allosteric sites on Ras for lead generation. PLoS ONE 2011;6:e25711.
64. Holzapfel G, Buhrman G, Mattos C. Shift in the equilibrium between on and off states of the allosteric switch in Ras-GppNHp affected by small molecules and bulk solvent composition. Biochemistry 2012;51:6114-26.
65. Vetter IR, Arndt A, Kutay U, Gorlich D, Wittinghofer A. Structural view of the Ran-Importin beta interaction at 2.3 A resolution. Cell 1999;97:635-46.
66. Thapar R, Williams JG, Campbell SL. NMR characterization of full-length farnesylated and non-farnesylated H-Ras and its implications for Raf activation. J Mol Biol 2004;343:1391-408.
67. Franken SM, Scheidig AJ, Krengel U, Rensland H, Lautwein A, Geyer M, et al. Three-dimensional structures and properties of a transforming and a nontransforming glycine-12 mutant of p21H-ras. Biochemistry 1993;32:8411-20.
68. Gibbs JB, Schaber MD, Allard WJ, Sigal IS, Scolnick EM. Purification of ras GTPase activating protein from bovine brain. Proc Natl Acad Sci U S A 1988;85:5026-30.
69. Gremer L, Gilsbach B, Ahmadian MR, Wittinghofer A. Fluoride complexes of oncogenic Ras mutants to study the Ras-RasGap interaction. Biol Chem 2008;389:1163-71.
70. Vogel US, Dixon RA, Schaber MD, Diehl RE, Marshall MS, Scolnick EM, et al. Cloning of bovine GAP and its interaction with oncogenic ras p21. Nature 1988;335:90-3.
71. Smith MJ, Ikura M. Integrated RAS signaling defined by parallel NMR detection of effectors and regulators. Nat Chem Biol 2014;10:223-30.
72. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation, and drug resistance. Biochim Biophys Acta 2007;1773:1263-84.
73. Buhrman G, Wink G, Mattos C. Transformation efficiency of RasQ61 mutants linked to structural features of the switch regions in the presence of Raf. Structure 2007;15:1618-29.
74. Krengel U, Schlichting I, Scherer A, Schumann R, Frech M, John J, et al. Three-dimensional structures of H-ras p21 mutants: molecular basis for their inability to function as signal switch molecules. Cell 1990;62:539-48.
75. Ahmadian MR, Zor T, Vogt D, Kabsch W, Selinger Z, Wittinghofer A, et al. Guanosine triphosphatase stimulation of oncogenic Ras mutants. Proc Natl Acad Sci U S A 1999;96:7065-70.
76. Huang L, Hofer F, Martin GS, Kim SH. Structural basis for the interaction of Ras with RalGDS. Nat Struct Biol 1998;5:422-6.
77. Pacold ME, Suire S, Perisic O, Lara-Gonzalez S, Davis CT, Walker EH, et al. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell 2000;103:931-43.
78. Stieglitz B, Bee C, Schwarz D, Yildiz O, Moshnikova A, Khokhlatchev A, et al. Novel type of Ras effector interaction established between tumour suppressor NORE1A and Ras switch II. EMBO J 2008;27:1995-2005.
79. Abankwa D, Gorfe AA, Hancock JF. Mechanisms of Ras membrane organization and signalling: Ras on a rocker. Cell Cycle 2008;7:2667-73.
80. Kapoor S, Weise K, Erlkamp M, Triola G, Waldmann H, Winter R. The role of G-domain orientation and nucleotide state on the Ras isoform-specific membrane interaction. Eur Biophys J 2012;41:801-13.
81. Abraham SJ, Nolet RP, Calvert RJ, Anderson LM, Gaponenko V. The hypervariable region of K-Ras4B is responsible for its specific interactions with calmodulin. Biochemistry 2009;48:7575-83.
82. Lopez-Alcala C, Alvarez-Moya B, Villalonga P, Calvo M, Bachs O, Agell N. Identification of essential interacting elements in K-Ras/calmodulin binding and its role in K-Ras localization. J Biol Chem 2008;283:10621-31.
83. Villalonga P, Lopez-Alcala C, Bosch M, Chiloeches A, Rocamora N, Gil J, et al. Calmodulin binds to K-Ras, but not to H- or N-Ras, and modulates its downstream signaling. Mol Cell Biol 2001;21:7345-54.
84. Wu LJ, Xu LR, Liao JM, Chen J, Liang Y. Both the C-terminal polylysine region and the farnesylation of K-RasB are important for its specific interaction with calmodulin. PLoS One 2011;6:e21929.
85. Peyroche A, Antonny B, Robineau S, Acker J, Cherfils J, Jackson CL. Brefeldin A acts to stabilize an abortive ARF-GDP-Sec7 domain protein complex: involvement of specific residues of the Sec7 domain. Mol Cell 1999;3:275-85.
86. Nussinov R, Tsai CJ, Mattos C. "Pathway drug cocktail": targeting Ras signaling based on structural pathways. Trends Mol Med 2013;19:695-704.